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In normal cells, p53 is maintained at a low level by ubiquitin-mediated proteolysis, but after genotoxic insult
this process is inhibited and p53 levels rise dramatically. Ubiquitination of p53 requires the ubiquitin-
activating enzyme Ubc5 as a ubiquitin conjugation enzyme and Mdm2, which acts as a ubiquitin protein ligase.
In addition to the N-terminal region, which is required for interaction with Mdm2, the C-terminal domain of
p53 modulates the susceptibility of p53 to Mdm2-mediated degradation. To analyze the role of the C-terminal
domain in p53 ubiquitination, we have generated p53 molecules containing single and multiple lysine-to-
arginine changes between residues 370 and 386. Although wild-type (WT) and mutant molecules show similar
subcellular distributions, the mutants display a higher transcriptional activity than WT p53. Simultaneous
mutation of lysine residues 370, 372, 373, 381, 382, and 386 to arginine residues (6KR p53 mutant) generates
a p53 molecule with potent transcriptional activity that is resistant to Mdm2-induced degradation and is
refractory to Mdm2-mediated ubiquitination. In contrast to WT p53, transcriptional activity directed by the
6KR p53 mutant fails to be negatively regulated by Mdm2. Those differences are also manifest in HeLa cells
which express the human papillomavirus E6 protein, suggesting that p53 C-terminal lysine residues are also
implicated in E6-AP-mediated ubiquitination. These data suggest that p53 C-terminal lysine residues are the
main sites of ubiquitin ligation, which target p53 for proteasome-mediated degradation.
Cell cycle arrest, DNA repair, and apoptosis are the most
common responses to DNA damage in normal mammalian
cells. Genetic instability and malignant transformation are con-
sequences of improper DNA damage responses (9, 26, 32).
The p53 protein plays an important role in the initiation of the
DNA damage response, cell cycle arrest, and tumor suppres-
sion (25, 31). One of the best-characterized functions of p53 is
its transcriptional activity (26, 32). p53 increases the transcrip-
tion of genes coding for important cell growth inhibitors, such
as the p21Waf1/Cip1 gene (10), and apoptotic genes, such as that
coding for Bax (42). The identification of the Mdm2 gene as a
p53 target gene, the product of which can negatively regulate
p53 functions, revealed a feedback loop that regulates both p53
activity and expression of Mdm2 (3, 30, 43, 44, 65).
In normal cells p53 levels are maintained at low or unde-
tectable levels by continual proteolytic degradation, but when
cells are exposed to stress signals, such as hypoxia and DNA
damage, degradation is inhibited and p53 levels rise (25, 35).
Sustained degradation of p53 is mediated by the ubiquitin-
proteasome pathway (34) and is carried out by the ubiquitin-
activating enzyme (E1), a ubiquitin-conjugating enzyme
(Ubc5), and a ubiquitin protein ligase (Mdm2) (13, 19). Ubiq-
uitin molecules are attached to p53 by an isopeptide bond
between the C terminus of ubiquitin and the e -amino group of
a lysine residue. Multiple ubiquitin molecules are required to
target protein substrates for degradation (18). Since degrada-
tion is an efficient means to abrogate all p53 functions, p53-
induced transcription of Mdm2 generates an efficient mecha-
nism for controlling p53 levels (3, 65). Many tumors and tumor
cell lines have low levels of Mdm2 because they express tran-
scriptionally inactive p53, and as a consequence, p53 levels are
very high (41). The importance of this regulatory mechanism is
illustrated by the fact that deletion of the mdm2 gene in mice
induces an early embryonic lethality which is rescued by dele-
tion of the p53 gene (24). A wide variety of mechanisms have
been proposed which can block the interaction of Mdm2 with
p53 and as a consequence increase the levels of p53. Phosphor-
ylation of p53 or Mdm2 by a DNA-dependent protein kinase
reduces the interaction between the two molecules (37, 58),
resulting in reduced ubiquitination of p53 by the ubiquitin
ligase activity of Mdm2 (20). The tumor suppressor p19 ARF
blocks the degradation of p53 by directly inhibiting the ubiq-
uitin ligase activity of Mdm2 (20, 39) and sequestering Mdm2
in the nucleolus (64, 66).
Subcellular distribution plays an important role in the con-
trol of p53 transcriptional activity, and nuclear transport is
dependent on three nuclear localization signals (NLSs) located
in the C-terminal region of the protein (57). Fusion of the
major NLS (NLSI, amino acids [aa] 316 to 322) to a heterol-
ogous cytoplasmic protein directs the chimeric protein to the
nucleus (7), while NLSII (aa 370 to 377) and NLSIII (aa 380 to
386) appear to increase the efficiency of nuclear import (57).
Moreover, it has been proposed that the interaction of lysine
305 with the cytoplasmic sequestration domain (aa 326 to 355)
regulates p53 subcellular distribution (33). The cytoplasmic
sequestration domain also contains the p53 oligomerization
domain and a putative leucine-rich nuclear export signal (LR-
NES) (aa 340 to 351) (60). Mdm2-mediated p53 degradation
has been reported to be a cytoplasmic process dependent on an
LR-NES present in Mdm2 (54). Consequently, p53 degrada-
tion is blocked by leptomycin B (12, 29), which is a competitive
inhibitor of the LR-NES receptor CRM1 (1, 11, 46, 62).
The p53-Mdm2 interaction is mediated by the N-terminal
regions of the proteins. Mdm2 can negatively regulate p53
transcriptional activity by binding to and occluding the p53
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transcriptional activation domain (5, 43, 45). The C-terminal
region of p53 modulates the susceptibility of p53 to Mdm2-
mediated degradation, and deletion of the last 30 aa of p53
inhibits this process (28). Six of the C-terminal 30 aa of p53 are
lysine residues which are potential sites of ubiquitination. To
investigate the role of the C-terminal lysine residues in the
degradation of p53, we have generated single and multiple
K-to-R changes in this region of p53. The altered proteins
display an increased ability to activate a p53-dependent tran-
scriptional reporter, and this ability is maximal with the p53
mutant in which all six lysine residues have been changed to
arginine residues. In vivo ubiquitination and degradation as-
says and in vitro ubiquitination assays suggest that p53 C-
terminal lysine residues are involved in ubiquitin-mediated
degradation of p53. Our results also support the notion that
Mdm2-mediated ubiquitination is an important mechanism for
controlling p53 activity.
MATERIALS AND METHODS
Proteins and antibodies. Ubiquitin was purchased from Sigma. Human E1
ubiquitin-activating enzyme was purified from recombinant baculovirus-infected
cells as described previously (53). Human Mdm2 (residues 6 to 491) was ex-
pressed in bacteria and purified as previously described for p53 (40). Human
Ubc5 was expressed in bacteria and purified as previously described (49). Glu-
tathione S-transferase (GST)–Mdm2 fusion protein was purified as reported
previously (4). Monoclonal antibody 4B2 (5) recognizes Mdm2. Monoclonal
antibody DO.1 (63) and polyclonal antibody CM1 recognize p53. Green fluores-
cent protein (GFP) was detected with a mixture of two mouse monoclonal
antibodies (anti-GFP clones 7.1 and 13.1) purchased from Boehringer Mann-
heim.
Plasmid construction. The previously described wild-type (WT) p53 BamHI-
EcoRI cassette (49) was replaced to generate multiple K-to-R mutants by site-
directed mutagenesis using a PCR strategy. DNA sequences were determined by
the University of St. Andrews DNA sequencing facility (with an ABI 377 se-
quencer). The pcDNA3-Mdm2 plasmid was described previously (39). The
pEGFP-C2 plasmid was purchased from Clontech.
Cell culture and transfections. HeLa, p53 null (Saos-2 and H1299), and mouse
p532/2 Mdm22/2 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum. Cells were transfected by
electroporation (950 mF, 240 V; Equibio Easyject Plus) as previously described
(49) or with Lipofectamine (GIBCO/BRL). pG13-luciferase (pG13-Luc) re-
porter assays were performed with 2 mg of reporter plasmid and 5 ng of plasmid
encoding WT p53 or one of the K-to-R p53 mutants per 106 Saos-2 cells. Ten
nanograms of p53-encoding and 30 ng of Mdm2-encoding plasmids were used for
cotransfection into p532/2 Mdm22/2 cells. Reporter assays in HeLa cells were
performed with 5 ng of WT p53 or the 6KR mutant. Empty pcDNA3 vector was
used to maintain a constant level of plasmid DNA. After electroporation, cells
were grown in six-well plates for 10 to 12 h and processed for luciferase activity
as previously described (51). For immunofluorescence, 105 cells were cotrans-
fected with 375 ng of plasmid encoding WT p53 or a K-to-R mutant and 2.125 mg
of Bluescript plasmid DNA. Mdm2-directed degradation in vivo was performed
with 200 ng of WT p53 or K-to-R mutants, 1.2 mg of Mdm2, and 600 ng of
GFP-encoding plasmids per 106 cells. Empty pcDNA3 vector was used to main-
tain a constant level of plasmid DNA. Transfected cells were divided into two
groups, and after 16 h in culture one of the groups was harvested. The second
group of Mdm2-transfected cells was treated for 4 h prior to harvesting with 10
mM MG132. p53 ubiquitination in vivo was detected in 1.5 3 105 p532/2
Mdm22/2 cells transfected with 200 ng of GFP, 200 ng of WT p53 or K-to-R p53
mutants, and 600 ng of pcDNA3 or an Mdm2-encoding plasmid. After 16 h in
culture, Mdm2-transfected cells were treated with 10 mM MG132 for 4 h prior to
harvesting. A total of 106 HeLa cells were cotransfected with 4 mg of an SV5-
tagged version of b-galactosidase (27) and 4 mg of WT p53- and 6KR-encoding
plasmids. After 16 h, cells were lysed and analyzed by Western blotting.
Immunofluorescence. After transfection, H1299 or Saos-2 cells were cultured
on glass or Permanox chamber slides (Nunc). Twenty-four hours after transfec-
tion, slides were washed in phosphate-buffered saline (PBS)–1 mM MgCl2, fixed
for 8 min in cold methanol-acetone (1:1), rinsed in PBS–1 mM MgCl2–0.1%
Tween 20, and incubated for 1 h at room temperature with DO.1 mouse mono-
clonal antibody diluted in DMEM–10% fetal calf serum. Slides were washed two
times in PBS–1 mM MgCl2, rinsed in PBS–1 mM MgCl2–0.1% Tween 20, and
incubated with a mixture of fluorescein isothiocyanate-conjugated donkey anti-
mouse immunoglobulin G in DMEM–10% fetal calf serum at the dilution spec-
ified by the manufacturer (Jackson ImmunoResearch Laboratories) for 30 min at
room temperature. After two washes in PBS–1 mM MgCl2 and rinsing in PBS–1
mM MgCl2–0.1% Tween 20, the slides were mounted with Mowiol-Dabco, dried,
and analyzed using a Bio-Rad MRC 600 LSM confocal microscope and custom
Bio-Rad software.
Western blotting. Whole-cell extracts were lysed in sodium dodecyl sulfate
(SDS) sample buffer as described previously (8). Lysates were boiled for 10 min
prior to fractionation by electrophoresis in 10% polyacrylamide gels containing
SDS. Proteins were transferred to a polyvinylidene difluoride membrane (Sigma)
by electroblotting. p53 (DO.1), Mdm2 (4B2), and GFP monoclonal antibodies
were used as primary antibodies. Blots were developed with an enhanced chemi-
luminescence detection system.
Interaction of Mdm2 and p53 in vitro. [35S]methionine-labeled in vitro-tran-
scribed and -translated p53 proteins (10 ml) were incubated for 2 h at 4°C with
1 mg of GST or GST-Mdm2 prebound to glutathione-agarose beads in 200 ml of
previously described binding buffer (21). For immunoprecipitation, [35S]methi-
onine-labeled in vitro-cotranscribed and -cotranslated Mdm2 and p53 proteins
(20 ml) were incubated for 2 h at 4°C with an equal mixture of protein A- and
protein G-agarose beads (Sigma) and p53-specific polyclonal antibody CM1 in
200 ml of previously described binding buffer (21). Beads were washed as de-
scribed previously (21), and bound protein was fractionated in a 10% polyacryl-
amide gel containing SDS. The dried gel was analyzed by phosphorimaging.
In vitro ubiquitination assays. [35S]methionine-labeled in vitro-transcribed
and -translated p53 proteins were used in ubiquitination assays as previously
reported (49). Reaction products were fractionated in a 10% polyacrylamide gel
containing SDS, and dried gels were analyzed by phosphorimaging (Fijix BAS
1500, MacBAS software). Ubiquitinated p53 was quantified by determining the
proportion of the total radioactive p53 that migrated more slowly than unmod-
ified p53.
RESULTS
K-to-R p53 mutants show higher transcriptional activity
than does WT p53. Reporter assays have been used previously
to identify lysine residues which are targets for ubiquitination
of transcriptionally active proteins or of transcriptional regu-
lators (2, 51). The C-terminal 30 aa of p53 are required for
Mdm2-mediated degradation (28) and contain six lysine resi-
dues which are potential targets for ubiquitination. To inves-
tigate the role of these residues on ubiquitin-proteasome-de-
pendent degradation of p53, single and multiple K-to-R
changes were introduced into the C-terminal region of p53
(Fig. 1). It was previously reported that K386R p53 has an
inherently higher transcriptional activity than does WT p53
(49). To test if other K-to-R mutations have similar conse-
quences on p53 transcriptional activity, Saos-2 cells, which lack
endogenous p53, were cotransfected with the p53-responsive
reporter plasmid pG13-Luc and expression plasmids for WT
p53 and K-to-R p53 mutants. WT p53 activated transcription
57-fold, while all K-to-R p53 mutants showed higher transcrip-
tional rates (Fig. 2A). The previously reported K386R mutant
was the single-point mutant with the highest transcriptional
activity (284-fold activation). The triple mutant 3CKR (483-
fold activation) showed a higher transcriptional activity than
did 3NKR (268-fold activation), suggesting that lysine residues
381, 382, and 386 may be the preferred targets for ubiquitina-
tion. However, 6KR p53, in which all six lysine residues are
changed to arginine, displayed the highest transcriptional ac-
tivity (613-fold activation). To confirm these results, the same
p53 expression plasmids were cotransfected with the Mdm2-
Luc reporter plasmid into Saos-2 cells or with the pG13-Luc
reporter plasmid into H1299 p53 null cells, with similar results
in each case (data not shown). This effect is likely to be medi-
ated by Mdm-2, as p532/2 Mdm22/2 cells cotransfected with
pG13-Luc and plasmids encoding p53 mutants did not show
significant differences in their abilities to activate the reporter
(see Fig. 8). This indicates that WT p53 and various K-to-R
mutants have inherently similar transcriptional activation po-
tential and that the observed differences in reporter activity are
a reflection of the susceptibility of these proteins to ubiquitin-
mediated proteolysis.
Subcellular localization of K-to-R p53 mutants is similar to
that of WT p53. p53 lysine residues 370, 372, 373, 381, 382, and
386 represent the basic amino acid core of both p53 NLSII and
NLSIII (57). Although NLSI (aa 316 to 322) is the predomi-
nant nuclear import signal in p53 (7, 57) and conservative
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K-to-R changes were introduced to create the p53 mutants, it
was important to eliminate the possibility that the differences
in transcriptional activity were a consequence of altered nu-
clear import. To establish this point, H1299 cells were trans-
fected with WT p53 or K-to-R p53 mutants, and the subcellular
localization of p53 was determined by indirect immunofluores-
cence with a p53-specific monoclonal antibody. WT p53 and
K-to-R p53 mutants showed similar subcellular distributions.
Ninety percent of transfected cells showed exclusive nuclear
localization of immunoreactive p53 (Fig. 3). In the remaining
10% of transfected cells, p53 was found in both the nucleus and
the cytoplasm. Similar results were obtained in Saos-2 cells
(data not shown). These results suggest that the differences in
transcriptional activity observed between WT p53 and K-to-R
mutants cannot be explained by differences in subcellular lo-
calization.
C-terminal lysine residues of p53 control Mdm2-directed
degradation of p53. To assess the role of p53 C-terminal lysine
residues in Mdm2-directed degradation of p53, K-to-R p53
mutants were either expressed alone or coexpressed with
Mdm2 in Saos-2 cells. p53 and Mdm2 expression were ana-
lyzed by Western blotting, and p53 molecules containing single
or double K-to-R changes all appeared to be susceptible to
Mdm2-induced degradation (Fig. 4A). In contrast, p53 mutant
6KR was resistant to Mdm2-mediated degradation. Under
these conditions, Mdm2 was detected only when the film was
overexposed but was at a relatively constant level in each case
(data not shown). GFP expressed from a cotransfected plasmid
was used as an internal control and indicated that the observed
differences were not due to variations in gel loading or trans-
fection efficiency. The remaining 50% of transfected cells were
pretreated with proteasome inhibitor MG132 for 4 h prior to
harvest and Western blot analysis, as described above. As ex-
pected, MG132 blocked Mdm2-directed degradation of p53
proteins (Fig. 4B). Concomitant accumulation of p53 and
Mdm2 after MG132 treatment confirmed that degradation of
both proteins is proteasome mediated. Although 6KR was
resistant to Mdm2-mediated degradation, limited degradation
could be observed when Mdm2 was expressed at high levels,
suggesting that alternative lysine residues can be used to me-
FIG. 1. Schematic representation of p53 mutants with C-terminal K-to-R changes.
FIG. 2. p53 mutants containing C-terminal K-to-R substitutions show higher
transcriptional activity than does WT p53. Saos-2 cells were cotransfected by
electroporation with expression plasmids for WT p53 or K-to-R mutants and the
pG13-Luc reporter plasmid. Each point is the mean of four independent trans-
fections, with error bars representing 1 standard deviation.
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diate p53 degradation (data not shown). Thus, lysine residues
370, 372, 373, 381, 382, and 386 have an important role in the
Mdm2-mediated degradation of p53.
K-to-R mutations in the C terminus of p53 do not affect its
interaction with Mdm2. In addition to the N-terminal region,
which is required for interaction with Mdm2, it has been sug-
gested that the conformation of the C-terminal region of p53
may be important for targeting Mdm2-dependent p53 ubiquiti-
nation (20). To exclude the possibility that the observed resis-
tance of 6KR to Mdm2-mediated degradation results from a
failure to bind Mdm2, this interaction was analyzed in vitro. In
vitro-translated and 35S-labeled WT p53 and K-to-R mutants
were allowed to interact with GST-Mdm2, and the bound pro-
teins were analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE) and phosphorimaging. No differences were observed
between the binding abilities of WT and mutant p53 molecules
(Fig. 5A). The observed interactions were specific, since GST
alone did not interact with p53 and GST-Mdm2 failed to in-
teract with 35S-labeled NF-kB p50 (Fig. 5A). Similar results
were obtained by coimmunoprecipitation of Mdm2 and p53
molecules (which were generated by cotranslation in vitro)
using anti-p53 antibody (Fig. 5B). Thus, C-terminal K-to-R
point mutations do not affect the ability of p53 to be recog-
nized by Mdm2.
p53 C-terminal lysine residues are targets for Mdm2-depen-
dent ubiquitination of p53. Since lysine residues are targets for
ubiquitination, it is likely that the inability of the 6KR mutant
to undergo Mdm2-dependent degradation is due to the fact
that it cannot be ubiquitinated. To test this hypothesis, WT p53
and K-to-R mutants were expressed alone or together with
Mdm2 in p532/2 Mdm22/2 cells. Twelve hours after transfec-
tion, Mdm2-transfected cells were exposed to 10 mM MG132
for 4 h. Whole-cell extracts were analyzed by Western blotting
with the DO.1 monoclonal antibody. Slowly migrating forms of
p53, consistent with ubiquitination, were observed with WT
p53 and the K386R and 3NKR mutants (Fig. 6A and B). In the
absence of proteasome inhibitor, p53 ubiquitinated forms were
observed only when film was overexposed (Fig. 6A, lanes 1 and
2). The appearance of slowly migrating forms was reduced for
the 3CKR mutant and virtually eliminated for the 6KR mutant.
GFP expressed from a cotransfected plasmid was also analyzed
by Western blotting, and the results indicated that the ob-
served differences were not due to variations in gel loading or
transfection efficiency. The relatively small proportion of p53
that accumulated as ubiquitinated products was a consequence
of the intracellular removal of ubiquitin by multiple ubiquitin
C-terminal hydrolases. Similar results were obtained for the
H1299 and Saos-2 cell lines (data not shown). Ubiquitination
of WT p53 and the 6KR mutant was also compared in an in
vitro system containing 35S-labeled substrate, ubiquitin, and
purified recombinant E1, Ubc5, and Mdm2 (49). Phosphorim-
ager quantification of ubiquitin adducts indicated that ubiq-
uitination of the 6KR mutant was reduced by 40% compared
to that of WT p53 (Fig. 6C). We conclude that C-terminal
lysine residues are involved in the Mdm2-mediated ubiquiti-
nation of p53.
Role of p53 C-terminal lysine residues in E6- and E6-AP-
mediated p53 degradation. To investigate the role of p53 C-
FIG. 3. Subcellular localization of WT p53 and mutants with C-terminal K-to-R changes. H1299 cells were transfected with empty pcDNA3 vector (a) and plasmids
expressing WT p53 (b), 6KR (c), 3NKR (d), 3CKR (e), K372/373R (f), K381/382R (g), K370R (h), and K386R (i). Indirect immunofluorescence with antibody against
p53 DO.1 is shown.
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terminal lysine residues in E6-AP-mediated degradation,
HeLa cells which express the E6 protein of human papilloma-
virus (HPV) were cotransfected with WT p53 or the 6KR
mutant, together with SV5-tagged b-galactosidase expression
plasmids. Twenty-four hours after transfection, whole-cell ex-
tracts were analyzed by Western blotting with a monoclonal
antibody recognizing p53. Higher levels of the 6KR mutant
than of WT p53 were observed (Fig. 7A). Similar results were
obtained with a polyclonal antibody to p53 (data not shown).
The increased accumulation of 6KR compared to WT p53 was
not due to variations in transfection efficiency, because these
differences were not reflected in the levels of the cotransfected
SV5-tagged b-galactosidase used as an internal control. To
confirm these results, HeLa cells were cotransfected with the
pG13-Luc reporter plasmid and expression plasmids for WT
p53 or the 6KR mutant. The 6KR mutant showed three times
more transcriptional activity than did WT p53 (Fig. 7B). Thus,
it is likely that p53 C-terminal lysine residues are also targets
for E6-AP-mediated regulation.
The susceptibility of p53 to ubiquitination correlates with
the ability of Mdm2 to negatively regulate p53-dependent tran-
scription. To evaluate the contribution of p53 degradation to
the negative regulation of p53 functions by Mdm2, we cotrans-
fected p532/2 Mdm22/2 cells with WT p53 and the K386R,
3NKR, 3CKR, and 6KR mutants and the p53 reporter plasmid
pG13-Luc in the absence or presence of an Mdm2 expression
plasmid. It was reasoned that K-to-R mutants resistant to
Mdm2-mediated ubiquitination and degradation may show
some resistance to the Mdm2-mediated negative regulation of
p53-dependent transcription. Mdm2 expression reduced WT
p53-dependent transcription by 60 to 70% (Fig. 8). Reductions
of 40 to 60% of transcriptional activity were observed when the
K386R, 3NKR, and 3CKR mutants were cotransfected with
Mdm2 (Fig. 8). In contrast, 6KR transcriptional activity was
not significantly reduced by Mdm2 (Fig. 8). Our results suggest
that ubiquitin-proteasome-mediated degradation of p53 is a
major function of Mdm2 that contributes to the negative reg-
ulation of p53-dependent transcriptional activity.
DISCUSSION
Degradation is the only mechanism which abrogates all func-
tions of p53, and in normal cells this is accomplished by the
ubiquitin-proteasome system (34). To identify lysine residues
which are the sites of modification by ubiquitin, a series of p53
molecules were created that contain lysine-to-arginine changes
in the C-terminal region of the protein. Using p53-dependent
reporter assays, we demonstrated that the p53 molecules con-
taining K-to-R changes display a higher transcriptional activity,
which is a reflection of their increased stability and resistance
to ubiquitin modification (Fig. 2). In addition to acting as a
ubiquitin protein ligase (19), it has been reported that Mdm2
negatively regulates p53 transcriptional activity by binding to
the transactivation domain of p53 (45, 65). Since p53 mutants
which accumulate may also induce more efficient synthesis of
Mdm2, differences in transcription are more obvious at early
stages after transfection. The observed transcriptional differ-
ences between K-to-R p53 mutants cannot be explained as a
consequence of conformational changes induced by the muta-
tions, since reporter assays performed in p532/2 Mdm22/2
cells showed no significant differences in the transactivation
potential of WT and mutant versions of p53 in the absence of
Mdm2 (Fig. 8). This result also suggests that Mdm2 is the key
regulatory molecule for the control of p53 stability. In HPV-
transformed cells p53 is regulated by the viral E6 protein,
which, in conjunction with E6-AP, targets p53 for ubiquitin-
mediated proteolysis. The 6KR mutant also appears to be
more resistant to degradation than WT p53 when introduced
into HeLa cells which constitutively express HPV E6. Because
complex formation between E6 and p53 is not mediated
through the C terminus of p53 (6, 36), and since WT p53 and
6KR showed similar subcellular distributions in HeLa cells
FIG. 4. Mdm2-mediated degradation is dependent on lysine residues in the C-terminal region of p53. Saos-2 cells were electroporated with plasmids encoding GFP,
WT p53, or K-to-R p53 mutants, together with empty pcDNA3 vector or Mdm2 vector as indicated. (A) Twenty-four hours after transfection, whole-cell extracts were
prepared and analyzed by Western blotting with anti-p53, anti-Mdm2, and anti-GFP monoclonal antibodies. (B) Transfected cells were treated with 10 mM MG132
for 4 h prior to harvest. Western blotting against p53 and Mdm2 was performed as described above.
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FIG. 5. K-to-R changes in the p53 C-terminal region do not affect p53-Mdm2 interaction. (A) 35S-labeled NF-kB (p50), WT p53, and K-to-R p53 mutants generated
by in vitro transcription and translation were incubated with GST-Mdm2 or GST as indicated. GST pull-down assays were performed at 4°C. Mdm2-associated material
was fractionated by SDS-PAGE, and the dried gel was analyzed by phosphorimaging (lower panel). (B) For coimmunoprecipitation, 35S-labeled Mdm2, DN Mdm2,
WT p53, and K-to-R p53 mutants generated by in vitro transcription and translation were incubated with protein A- and protein G-agarose beads and p53-specific
polyclonal antibody CM1, as indicated (IPa p53). p53-associated material was fractionated by SDS-PAGE, and the dried gel was analyzed by phosphorimaging (lower
panel).
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(data not shown), we conclude that E6-directed ubiquitination
may also target the C-terminal lysines of p53. However, it has
been reported that p53 mutants lacking residues 370 to 393 or
containing lysine-to-isoleucine changes at positions 381, 382,
and 386 are efficiently degraded after cotransfection with HPV
E6 into p532/2 mouse fibroblasts (6). Differences in the levels
of E6 between transfected and transformed cells and the extent
to which Mdm2 is activated by p53 under these different con-
ditions may go some way to explaining the variance of these
results. In an in vitro degradation system it was noted that
E6-mediated degradation of p53 containing K-to-I changes at
positions 381, 382, and 386 was less efficient than that of WT
p53 (6).
Conservative changes of K to R do not have consequences
for other p53 properties. Similar subcellular distributions were
observed for K-to-R p53 mutants and WT p53 when transiently
expressed in p53 null cells. Conservative changes in NLSII and
NLSIII do not affect the NLS function, and it has been shown
FIG. 6. p53 C-terminal lysine residues are targets for Mdm2-mediated ubiquitination. (A) Ubiquitination of p53 in vivo. p532/2 Mdm22/2 cells were cotransfected
with WT p53 and empty pcDNA3 vector or an Mdm2 expression plasmid and incubated with proteasome inhibitor MG132, as indicated. Whole-cell extracts were
analyzed by Western blotting with DO.1 anti-p53 monoclonal antibody. (B) p532/2 Mdm22/2 cells were cotransfected with a GFP-encoding plasmid and WT p53 or
K-to-R mutants, together with empty pcDNA3 vector or an Mdm2 expression plasmid. Cells were treated and analyzed as described above. After being stripped, the
membrane was incubated with Mdm2 and GFP antibodies. (C) In vitro ubiquitination (Ub) assays were performed with 35S-labeled WT p53 and the 6KR mutant.
Reaction products were fractionated by SDS-PAGE, and the dried gel was analyzed by phosphorimaging. p53-Ub, ubiquitin-conjugated forms of p53.
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that NLSI is the predominant NLS of p53 (7, 57). Likewise,
K-to-R p53 mutants show binding to Mdm2 similar to that of
WT p53. Thus, the transcriptional activity of K-to-R p53 mu-
tants cannot be explained by differences in nuclear localization
or Mdm2 binding.
Multiple sites for ubiquitin ligation are often required to
target a substrate for degradation (2, 51, 56, 61). Only the 6KR
mutant was resistant to Mdm2-mediated ubiquitination and
degradation under the experimental conditions used. Although
a dramatic reduction in the detection of ubiquitinated forms of
the 6KR mutant was observed in vivo, it should be noted that
when the Western blot was exposed for a long time, some
ubiquitinated forms could still be detected (data not shown),
suggesting that neighboring lysine residues, such as K351
and/or K357, may also be used as alternative ubiquitination
sites. This seems to be the case in vitro, where only a 40%
reduction in the amount of ubiquitinated forms of 6KR was
observed compared to that of WT p53. The remaining 60% of
ubiquitination in the 6KR mutant could also be explained by
the excess of E1, E2, and E3 used in our in vitro assay or the
absence of other cofactors regulating p53 ubiquitination. For
instance, the interaction of p19 ARF with Mdm2 inhibits the
ubiquitin ligase activity of Mdm2 (20, 39), and retinoblastoma
protein has been proposed to block Mdm2-mediated degrada-
tion of p53 (21). Together, our results suggest that the previ-
ously reported resistance to Mdm2-mediated degradation ob-
served in a p53 mutant lacking the extreme C-terminal 30 aa
(28) can be explained by the failure of this mutant to be
efficiently ubiquitinated (20).
Reporter assays performed in p532/2 Mdm22/2 cells show
that exogenous Mdm2 is incapable of inhibiting the transcrip-
tional activity of the 6KR mutant (Fig. 8). Therefore, the
predominant function of Mdm2 is to act as a ubiquitin protein
ligase rather than as a direct transcriptional inhibitor (13, 19,
20, 39). This is consistent with other published work which
indicates that under special circumstances, when p53 and
Mdm2 are present in the same cellular compartment, no inhi-
bition of p53-dependent transcription is observed. Thus, when
p53 and Mdm2 are retained in the nucleolus by treatment with
leptomycin B, p53 is transcriptionally active (29). Likewise,
c-Abl nonreceptor tyrosine kinase appears to stabilize p53 by
inhibiting Mdm2-mediated degradation. In this situation, p53
retains its transcriptional activity even though the amount of
FIG. 7. p53 C-terminal lysine residues are targets for E6-AP-mediated deg-
radation. (A) HeLa cells which express HPV E6 protein were cotransfected with
WT p53 or the 6KR mutant and SV5-tagged b-galactosidase expression plas-
mids. Twenty-four hours after transfection, whole-cell extracts were analyzed by
Western blotting with a monoclonal antibody to p53 (DO.1). After being
stripped, the membrane was blotted with SV5 antibody (b-gal SV5). (B) HeLa
cells were cotransfected with the pG13-Luc reporter plasmid and expression
plasmids for WT p53 or the 6KR mutant. Twelve hours after transfection,
reporter activity was determined. Each point is the mean of four independent
transfections, with error bars representing 1 standard deviation.
FIG. 8. Negative regulation of p53 transcriptional activity by Mdm2 requires
ubiquitin-mediated degradation. p532/2 Mdm22/2 cells were cotransfected with
the pG13-Luc reporter plasmid and expression plasmids for WT p53 or the 6KR
mutant, together with an empty vector or an Mdm2 expression plasmid. Twelve
hours after transfection, reporter activity was determined. Each point is the mean
of five independent transfections, with error bars representing 1 standard devi-
ation.
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p53 bound to Mdm2 does not change (59). It is now widely
accepted that several regions in p53 are required for Mdm2-
mediated degradation. It has been recently reported that a
region from aa 92 to 112 of p53 functions as a degradation
signal for Mdm2 (15). Interestingly, this region is part of an
extensive N-terminal PEST region in p53 (52) that is presum-
ably exposed on the surface of the protein, since it is suscep-
tible to proteolysis in vitro (47). Gu et al. (15) also recognize
that in addition to the N-terminal region of p53, the C-terminal
region of p53 also contributes to Mdm2-mediated degradation
of p53. Thus, it appears that Mdm2 binds to the N terminus of
p53 but directs ubiquitin ligation at the C terminus of p53.
A complex requirement for degradation is not confined to
p53, and striking similarities can be recognized between the
degradation of the NF-kB inhibitor protein IkBa and that of
p53. Degradation of both molecules seems to require both C-
and N-terminal regions, one of which contains a PEST region,
while the other contains lysine residues which are the targets
for ubiquitination (27, 48, 50–52). Moreover, the IkBa and p53
lysine residue implicated in SUMO-1 conjugation is also in-
volved in ubiquitination (8, 49). In fact, p53 mutant K386R,
which cannot conjugate SUMO-1 (49), is also the single-point
mutation with the highest transcriptional rate, suggesting that
lysine residue 386 may be a major ubiquitination site. Since
ubiquitin conjugation of the K386R mutant is possible, we can
conclude that SUMO-1 and ubiquitin conjugation of p53 do
not compete for the same lysine residue. However, since the
C-terminal region of p53 is recognized by both ubiquitin and
SUMO-1 enzymes, an interference between the two conjuga-
tion systems cannot be excluded. The balance between
SUMO-1 and ubiquitin conjugation may be critical for control-
ling p53 activity, because SUMO-1 conjugation activates p53
transcriptional activity (14, 49), while ubiquitination reduces
p53 levels and as a consequence abrogates these functions.
Other posttranslational modifications in the C terminus of
p53 have also been reported. Phosphorylation of serine resi-
dues 376, 378, and 392 (17, 22, 23, 38) and acetylation of lysine
residues 320 and 382 (16, 55) of p53 enhance sequence-specific
DNA binding in vitro. Interestingly, lysine residue 382 be-
comes acetylated and lysine residue 386 is conjugated to
SUMO-1 after cells are exposed to UV light (49, 55). In addi-
tion to their consequences for the transcriptional activity of
p53, those modifications may subtly influence p53 ubiquitina-
tion by altering the selection of lysine residues that are avail-
able for ubiquitination. Thus, phosphorylation, acetylation,
and SUMO-1 conjugation may contribute to the induction of
p53 responses after DNA damage, whereas the role of ubiq-
uitination is to maintain a low steady-state level of p53 in
normal cells. This fine balance allows the p53 system to quickly
respond to signals from the extracellular environment by dra-
matically increasing the levels and activity of p53.
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